FDA Approves Grand Pharmaceutical Group's Innovative SIR-Spheres Y-90 Resin Microsphere Injection Ahead of Schedule

Reuters

07/07

FDA Approves <a href="https://laohu8.com/S/CGPHF">Grand Pharmaceutical</a> Group's Innovative SIR-Spheres Y-90 Resin Microsphere Injection Ahead of Schedule

Grand Pharmaceutical Group Ltd. has announced that the U.S. Food and Drug Administration (FDA) has officially approved a new indication for their globally innovative radioactive product, SIR-Spheres® Y-90 Resin Microsphere Injection, ahead of schedule. This approval marks a significant milestone for the company, enhancing their portfolio of advanced treatment options. Additionally, the Group, in collaboration with Sirtex Medical Pty Limited, Telix Pharmaceuticals Limited, and ITM Isotope Technologies Munich SE, has been involved in establishing a world-class tumor intervention R&D platform. This collaboration highlights the combined efforts of multiple organizations in advancing medical innovation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief on July 07, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2549537129"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2549537129\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2549537129?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-07 21:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2549537129","market":"us","top_or_hot":-1,"title":"FDA Approves Grand Pharmaceutical Group's Innovative SIR-Spheres Y-90 Resin Microsphere Injection Ahead of Schedule","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      FDA Approves <a href=\"https://laohu8.com/S/CGPHF\">Grand Pharmaceutical</a> Group's Innovative SIR-Spheres Y-90 Resin Microsphere Injection Ahead of Schedule\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Grand Pharmaceutical Group Ltd. has announced that the U.S. Food and Drug Administration (FDA) has officially approved a new indication for their globally innovative radioactive product, SIR-Spheres® Y-90 Resin Microsphere Injection, ahead of schedule. This approval marks a significant milestone for the company, enhancing their portfolio of advanced treatment options. Additionally, the Group, in collaboration with Sirtex Medical Pty Limited, <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> Limited, and ITM Isotope Technologies Munich SE, has been involved in establishing a world-class tumor intervention R&amp;D platform. This collaboration highlights the combined efforts of multiple organizations in advancing medical innovation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief on July 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Approves Grand Pharmaceutical Group's Innovative SIR-Spheres Y-90 Resin Microsphere Injection Ahead of Schedule</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Approves Grand Pharmaceutical Group's Innovative SIR-Spheres Y-90 Resin Microsphere Injection Ahead of Schedule\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-07 21:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      FDA Approves <a href=\"https://laohu8.com/S/CGPHF\">Grand Pharmaceutical</a> Group's Innovative SIR-Spheres Y-90 Resin Microsphere Injection Ahead of Schedule\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Grand Pharmaceutical Group Ltd. has announced that the U.S. Food and Drug Administration (FDA) has officially approved a new indication for their globally innovative radioactive product, SIR-Spheres® Y-90 Resin Microsphere Injection, ahead of schedule. This approval marks a significant milestone for the company, enhancing their portfolio of advanced treatment options. Additionally, the Group, in collaboration with Sirtex Medical Pty Limited, <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> Limited, and ITM Isotope Technologies Munich SE, has been involved in establishing a world-class tumor intervention R&amp;D platform. This collaboration highlights the combined efforts of multiple organizations in advancing medical innovation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief on July 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00512","symbol_name":"遠大醫藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250707:nNDL8XVgZg:1","article_id":"2549537129","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549537129","pubTimestamp":1751893486,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Grand Pharmaceutical Group Ltd. has announced that the U.S. Food and Drug Administration  has officially approved a new indication for their globally innovative radioactive product, SIR-Spheres Y-90 Resin Microsphere Injection, ahead of schedule. This approval marks a significant milestone for the company, enhancing their portfolio of advanced treatment options. Additionally, the Group, in collaboration with Sirtex Medical Pty Limited, Telix Pharmaceuticals Limited, and ITM Isotope Technologies Munich SE, has been involved in establishing a world-class tumor intervention R&D platform. This collaboration highlights the combined efforts of multiple organizations in advancing medical innovation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00512":"远大医药","BK1191":"制药","TLX.AU":"TELIX PHARMACEUTICALS LTD","BK7067":"生物科技"},"translate_title":"FDA提前批准远大医药集团创新型SIR-Spheres Y-90树脂微球注射液","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00512":0.9,"TLX.AU":0.9},"content_text":"FDA Approves Grand Pharmaceutical Group's Innovative SIR-Spheres Y-90 Resin Microsphere Injection Ahead of Schedule\n    \n\n        Grand Pharmaceutical Group Ltd. has announced that the U.S. Food and Drug Administration (FDA) has officially approved a new indication for their globally innovative radioactive product, SIR-Spheres® Y-90 Resin Microsphere Injection, ahead of schedule. This approval marks a significant milestone for the company, enhancing their portfolio of advanced treatment options. Additionally, the Group, in collaboration with Sirtex Medical Pty Limited, Telix Pharmaceuticals Limited, and ITM Isotope Technologies Munich SE, has been involved in establishing a world-class tumor intervention R&D platform. This collaboration highlights the combined efforts of multiple organizations in advancing medical innovation.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief on July 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}